Spatholobus suberectus Column Extract Inhibits Estrogen Receptor Positive Breast Cancer via Suppressing ER MAPK PI3K/AKT Pathway

Evidence-based Complementary and Alternative Medicine

Volumn 2016, Issue , 2016, Pages

  Sun, Jia Qi ^a   Zhang, Gan Lin ^a   Zhang, Yi ^a   Nan, Nan ^a   Sun, Xu ^a   Yu, Ming Wei ^a   Wang, Hong ^a   Li, Jin Ping ^a,b   Wang, Xiao Min ^a  

^a BEIJING HOSPITAL OF TRADITIONAL CHINESE MEDICINE AFFILIATED TO CAPITAL MEDICAL UNIVERSITY   (China)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYBENZOIC ACID; ANTINEOPLASTIC AGENT; CALYCOSIN; DAIDZEIN; EPICATECHIN; FLAVONOID; FORMONONETIN; GENISTEIN; GLYCYRRHIZIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHYTOESTROGEN; PLANT EXTRACT; PROTEIN KINASE B; PROTOCATECHUIC ACID; PRUNETIN; PUERARIN; SPATHOLOBUS SUBERECTUS COLUMN EXTRACT; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL MIGRATION; CELL VIABILITY; CHEMICAL COMPOSITION; CHINESE HERB; DRUG ISOLATION; DRUG SYNTHESIS; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MCF-7 CELL LINE; MTT ASSAY; SPATHOLOBUS SUBERECTUS; WESTERN BLOTTING;

EID: 85008888467     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2016/2934340     Document Type: Article

References (36)

1. L.A. Torre, F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-Tieulent, and A. Jemal, "Global cancer statistics, 2012, " CA: A Cancer Journal for Clinicians, vol. 65, no. 2, pp. 87-108, 2015.
2. R. L. Theriault, R. W. Carlson, C. Allred et al., "Breast cancer, version 3.2013: featured updates to the NCCN guidelines, " Journal of the National Comprehensive Cancer Network, vol. 11, no. 7, pp. 753-761, 2013.
3. T.De Marchi, J. A. Foekens, A. Umar, and J.W.Martens, "Endocrine therapy resistance in estrogen receptor (ER)-positive breast cancer, " Drug Discovery Today, vol. 21, no. 7, pp. 1181-1188, 2016.
4. S. Zhang and L. Xuan, "New phenolic constituents from the stems of Spatholobus suberectus, " Helvetica Chimica Acta, vol. 89, no. 6, pp. 1241-1245, 2006.
5. E.-Y. Su, Y.-H. Fang, and H.-S. Chen, "Clinical observation of treating 62 patients with severe aplastic anemia failing in immunosuppressive therapy by integrative medicine, " Zhongguo Zhong Xi Yi Jie He Za Zhi, vol. 32, no. 12, pp. 1616-1620, 2012.
6. Chinese Pharmacopoeia, China Medical Science Press, Beijing, China, 2010.
7. M.-H. Lee, Y.-P. Lin, F.-L. Hsu, G.-R. Zhan, and K.-Y. Yen, "Bioactive constituents of Spatholobus suberectus in regulating tyrosinase-related proteins and mRNA in HEMn cells, " Phytochemistry, vol. 67, no. 12, pp. 1262-1270, 2006.
8. T. Fleischer, T. Chang, J. Chiang, C. Chang, C. Hsieh, and H. Yen, "Adjunctive Chinese Herbal Medicine therapy improves survival of patients with chronic myeloid leukemia: A nationwide population-based cohort study, " Cancer Medicine, vol. 5, no. 4, pp. 640-648, 2016.
9. Y. Fu, Y. Cheng, J.-P. Chen, and D.-M. Wang, "Advances in studies on chemical constituents in Spatholobi Caulis and their pharmacological activities, " Chinese Traditional and Herbal Drugs, vol. 42, no. 6, pp. 1229-1234, 2011.
10. H. Hatcher, R. Planalp, J. Cho, F. M. Torti, and S. V. Torti, "Curcumin: fromancientmedicine to current clinical trials, " Cellular and Molecular Life Sciences, vol. 65, no. 11, pp. 1631-1652, 2008.
11. D. Lu, H.He, B.Wu, and S. Yao, "Cytotoxic effect on cancer cells and structural identification of phenols from Spatholobi caulis by HPLC-ESI-MS(n), " Natural Product Communications, vol. 4, no. 6, pp. 809-812, 2009.
12. B.-J. Lee, I.-Y. Jo, Y. Bu et al., "Antiplatelet effects of Spatholobus suberectus via inhibition of the glycoprotein IIb/IIIa receptor, " Journal of Ethnopharmacology, vol. 134, no. 2, pp. 460-467, 2011.
13. E.-S. Ha, E.-O. Lee, T.-J. Yoon et al., "Methylene chloride fraction of Spatholobi Caulis induces apoptosis via caspase dependent pathway in U937 cells, " Biological & Pharmaceutical Bulletin, vol. 27, no. 9, pp. 1348-1352, 2004.
14. J. D. Yager and N. E. Davidson, "Estrogen carcinogenesis in breast cancer, " The New England Journal of Medicine, vol. 354, no. 3, pp. 270-282, 2006.
15. E. L. Cavalieri, D. E. Stack, P. D. Devanesan et al., "Molecular origin of cancer: catechol estrogen-3, 4-quinones as endogenous tumor initiators, " Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 20, pp. 10937- 10942, 1997.
16. W. Horst-Sikorska and A. Wawrzyniak, "The role of hormonal therapy in osteoporosis, " Endokrynologia Polska, vol. 62, no. 1, pp. 61-64, 2011.
17. L.N. Petz, Y. S. Ziegler, M. A. Loven, and A.M.Nardulli, "Estrogen receptor and activating protein-1mediate estrogen responsiveness of the progesterone receptor gene in MCF-7 breast cancer cells, " Endocrinology, vol. 143, no. 12, pp. 4583-4591, 2002.
18. H.Wang, Y. Liu, Z. Zenc, and W. He, "Study onHPLCchromatographic fingerprint of anti-Tumor active site SSCE of Caulis spatholobi, " Zhongguo Zhongyao Zazhi, vol. 36, no. 18, pp. 2525- 2529, 2011.
19. C. R. Sirtori, A. Arnoldi, and S. K. Johnson, "Phytoestrogens: End of a tale?" Annals of Medicine, vol. 37, no. 6, pp. 423-438, 2005.
20. S. M. Mense, F. Remotti, A. Bhan et al., "Estrogen-induced breast cancer: Alterations in breast morphology and oxidative stress as a function of estrogen exposure, " Toxicology and Applied Pharmacology, vol. 232, no. 1, pp. 78-85, 2008.
21. H. Adlercreutz, "Phytoestrogens and breast cancer, " Journal of Steroid Biochemistry and Molecular Biology, vol. 83, no. 1-5, pp. 113-118, 2002.
22. G. Ursin, L. Bernstein, and M. C. Pike, "Breast cancer, " Cancer Surveys, vol. 19-20, pp. 241-264, 1994.
23. B. D. Bernardo, J. Z. Brandt, T. F. Grassi, L. T. R. Silveira, W. R. Scarano, and L. F. Barbisan, "Genistein reduces the noxious effects of in utero bisphenolAexposure on the rat prostate gland at weaning and in adulthood, " Food and Chemical Toxicology, vol. 84, pp. 64-73, 2015.
24. J. Wang, S. Jenkins, and C. A. Lamartiniere, "Cell proliferation and apoptosis in rat mammary glands following combinational exposure to bisphenol A and genistein, " BMC Cancer, vol. 14, article 379, 2014.
25. E. R. Levin, "Integration of the extranuclear and nuclear actions of estrogen, " Molecular Endocrinology, vol. 19, no. 8, pp. 1951- 1959, 2005.
26. P. Lopez-Bergami, C. Huang, J. S. Goydos et al., "Rewired ERKJNK signaling pathways in melanoma, " Cancer Cell, vol. 11, no. 5, pp. 447-460, 2007.
27. R. Wisdom, R. S. Johnson, and C. Moore, "c-Jun regulates cell cycle progression and apoptosis by distinct mechanisms, " The EMBO Journal, vol. 18, no. 1, pp. 188-197, 1999.
28. L. M. Smith, S. C. Wise, D. T. Hendricks et al., "cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype, " Oncogene, vol. 18, no. 44, pp. 6063-6070, 1999.
29. W. Hamilton-Burke, L. Coleman, M. Cummings et al., "Phosphorylation of estrogen receptor β at serine 105 is associated with good prognosis in breast cancer, " The American Journal of Pathology, vol. 177, no. 3, pp. 1079-1086, 2010.
30. H. Yamashita, M. Nishio, T. Toyama et al., "Low phosphorylation of estrogen receptor α (ERα) serine 118 and high phosphorylation of ERα serine 167 improve survival in ERpositive breast cancer, " Endocrine-Related Cancer, vol. 15, no. 3, pp. 755-763, 2008.
31. D. Zivadinovic, B. Gametchu, and C. S. Watson, "Membrane estrogen receptor-Alpha levels inMCF-7 breast cancer cells predict cAMP and proliferation responses, " Breast Cancer Research, vol. 7, no. 1, pp. R101-R112, 2005.
32. S. Kato, H. Endoh, Y. Masuhiro et al., "Activationof the estrogen receptor through phosphorylation by mitogen-Activated protein kinase, " Science, vol. 270, no. 5241, pp. 1491-1494, 1995.
33. M. Qi and E. A. Elion, "MAP kinase pathways, " Journal of Cell Science, vol. 118, no. 16, pp. 3569-3572, 2005.
34. C.-C. Su, J. Y.-F.Chen, Z.-H.Din et al., "13-Acetoxysarcocrassolide induces apoptosis on human gastric carcinoma cells through mitochondria-related apoptotic pathways: P38/JNK activation and PI3K/AKT suppression, " Marine Drugs, vol. 12, no. 10, pp. 5295-5315, 2014.
35. C. A. Castaneda, H. Cortes-Funes, H. L. Gomez, and E. M. Ciruelos, "The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer, " Cancer and Metastasis Reviews, vol. 29, no. 4, pp. 751-759, 2010.
36. S. Massarweh, C. K. Osborne, C. J. Creighton et al., "Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function, " Cancer Research, vol. 68, no. 3, pp. 826-833, 2008.